Aehr Test Systems Soars Again Friday. Shares Now Up More than 500% On the Year.

Shares of Aehr Test Systems (NASDAQ:AEHR) are up roughly 8% in Friday midday, after a fresh Wall Street initiation lit another fire under one of 2026’s most explosive small caps. The move extends a year-to-date advance of 510.7% and pushes the stock through its 52-week high of $133.35.

Jefferies Buy Rating and $175 Target Fuel the Move

Jefferies initiated coverage of Aehr today with a Buy rating and a $175 price target, and importantly, the firm called its own model conservative. “We see credible upside to our estimates, built only on programs already in production and backlog booked. Our model excludes memory, CPO, conversion of the AI benchmark customer, and a return to peak SiC,” Jefferies wrote. In plain English, the target does not require a silicon carbide recovery, a memory win, or the huge AI benchmark customer converting to production. Those are all free options.

The analyst also laid out the structural case: “We see AI/AP/SiPho as a significant LT catalyst, as rising chip value, higher power envelopes, chiplet/HBM integration, and compounding package-yield risk all increase reliability-test intensity.” Translation for a non-specialist reader. AI accelerators run hotter, cost more, and stack more dies into a single package. That makes it far more expensive to discover a bad chip late, so buyers want to screen at the wafer level before packaging. That’s exactly what Aehr’s FOX family of wafer-level burn-in systems and its Sonoma ultra-high-power packaged-part burn-in platform do.

Jefferies also flagged the mix shift as the real story: “AEHR has undergone one of the semi equipment sector’s most significant mix transformations, with SiC more than 90% of FY24 revenue and now AI over 90% of FY26 revenue. Additionally, the top customer has fallen from 79% of revenue in FY23 to an estimated over 25% in FY27E.” Customer concentration risk, long a bear pillar, is fading.

Test Equipment Peers Have Re-Rated, Too

Aehr is the standout, but the entire semiconductor test and inspection group has been one of 2026’s strongest pockets of the market. Teradyne (NASDAQ:TER | TER Price Prediction) is up 112% year to date and 261% over one year. Cohu (NASDAQ:COHU) has gained 151% YTD, FormFactor (NASDAQ:FORM) is up 136% YTD, and Onto Innovation (NYSE:ONTO) has advanced 114% YTD. Axcelis Technologies is the laggard of the group at 78% YTD.

The read-through is straightforward. AI chips are harder and more expensive to test than what came before, and every name that touches burn-in, probe, handlers, or wafer inspection is capturing that spend. Aehr’s gain still dwarfs the group, which cuts both ways: more upside already booked into the tape, but far more valuation risk if AI test intensity underdelivers.

Watch the Risk Behind the Rally

This is still a small cap with a market value around $4.35 billion, lumpy order-driven revenue (Q3 FY26 revenue was $10.31 million, down 43.7% YoY), and a beta of 3.09. Insiders have been steady sellers into the rally, including the CEO and CFO through July, per Form 4 filings. A stock up more than 500% year to date carries extreme valuation risk on any AI test-demand hiccup.

Keep an eye on the stock into the close to see if AEHR can hold this breakout above its prior 52-week high. The next catalyst is management’s fiscal 2027 order flow commentary, where the CEO has already guided to revenue of $130 million to $150 million.

Contact [email protected] for any questions or corrections.